9 Meters Biopharma ( ) - 株価, ニュースと分析DB:2Q3A

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

2Q3A 株式概要

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.

会社概要

2Q3A ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

Revenue is forecast to grow 56.58% per year

リスク分析

Negative shareholders equity

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($0)

+3 さらなるリスク

9 Meters Biopharma, Inc. 競合他社

Biofrontera

XTRA:B8FK

€18.2m

Apontis Pharma

XTRA:APPH

€71.6m

MPH Health Care

DB:93M1

€114.7m

PharmaSGP Holding

XTRA:PSG

€278.2m

価格と性能

の歴代最高値、変動、値下がりまとめ9 Meters Biopharma
過去の株価
現在の株価	US$0.24
52週高値	US$6.40
52週安値	US$0.24
ベータ	1.48
11ヶ月の変化	-62.84%
3ヶ月変化	-81.24%
1年変化	-94.67%
33年間の変化	-97.41%
5年間の変化	n/a
IPOからの変化	-97.83%

Recent updates

株主還元

	2Q3A	DE Pharmaceuticals	DE 市場
7D	-60.0%	-4.8%	0.8%
1Y	-94.7%	-19.4%	2.0%

業界別リターン: 2Q3A underperformed the German Pharmaceuticals industry which returned -10% over the past year.

リターン対市場: 2Q3A underperformed the German Market which returned 8.6% over the past year.

価格変動

Is 2Q3A's price volatile compared to industry and market?
2Q3A volatility
2Q3A Average Weekly Movement	19.9%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

安定した株価: 2Q3A's share price has been volatile over the past 3 months.

時間の経過による変動: 2Q3A's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	10	Bethany Sensenig	www.9meters.com

9 Meters Biopharma, Inc. 基礎のまとめ

9 Meters Biopharma の収益と売上を時価総額と比較するとどうか。
2Q3A 基礎統計学
時価総額	€8.01m
収益（TTM）	-€41.24m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-0.1x

PER（株価収益率

2Q3A は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
2Q3A 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$46.28m
収益	-US$46.28m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-3.20
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	-80.5%

2Q3A の長期的なパフォーマンスは？

過去の実績と比較を見る

This company listing is no longer active

2Q3A 株式概要

報酬

リスク分析

9 Meters Biopharma, Inc. 競合他社

XTRA:B8FK

€18.2m

XTRA:APPH

€71.6m

DB:93M1

€114.7m

XTRA:PSG

€278.2m

価格と性能

最新ニュース

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

株主還元

価格変動

会社概要

9 Meters Biopharma, Inc. 基礎のまとめ

0.0x

-0.1x

収益と収入